In this third and final segment in DAIC’s “One on One” series with Dr. Christine Seidman, learn what’s on the horizon at Harvard’s Seidman Lab, and how she views the value of learning from and mentoring a new generation of researchers. 

Part 1 in this 3-part series delved into the research and treatments of the heart muscle disorder, hypertropic cardiomyopathy. You can view VIDEO, Part 1: Hypertrophic Cardiomyopathy: One on One with a Cardiovascular Research Leader, here.

In Part 2 of this series with Dr. Christine Seidman, a discussion on the discovery of gene-based diagnostics at Harvard’s Seidman Lab which allowed for targeted disease treatment of hypertrophic cardiomyopathy. You can watch Part 2: Hypertrophic Cardiomyopathy in Focus, here.

Related Hypertrophic Cardiomyopathy content:

Part 1: Hypertrophic Cardiomyopathy: One on One with a Cardiovascular Research Leader

Part 2: Hypertrophic Cardiomyopathy in Focus

Imbria Pharmaceuticals Completes Enrollment in the Phase 2 IMPROVE-ISCHEMIA Clinical Trial of Ninerafaxstat in Patients with Stable Angina

Results from Two Phase 3 Studies Evaluating Mavacamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy Released

First International Guidelines on Heart Muscle Diseases Published

A 3-part video series with Christine E. Seidman, MD, FACC, FAHA

In the first of this 3-part “One on One” series, Dr. Christine Seidman — recognized as one of the world’s most respected physician scientists — delves into the research and treatments of the heart muscle disorder, hypertrophic cardiomyopathy.  

In part 2 of DAIC’s 3-part “One on One” series with Dr. Christine Seidman, a discussion on the discovery of gene-based diagnostics at Harvard’s Seidman Lab which allowed for targeted disease treatment of hypertrophic cardiomyopathy. Watch Part 2: Hypertrophic Cardiomyopathy in Focus, here.

Don’t miss the third and final segment in DAIC’s “One on One” series with Dr. Christine Seidman. Learn what’s on the horizon at Harvard’s Seidman Lab, and how she views the value of learning from and mentoring a new generation of researchers. 

Related Hypertrophic Cardiomyopathy content:

VIDEO, Part 3: Award-winning Researcher Shares Update on Hypertrophic Cardiomyopathy Work and Value of Mentoring

Part 2: Hypertrophic Cardiomyopathy in Focus

Part 1: Hypertrophic Cardiomyopathy: One on One with a Cardiovascular Research Leader

Imbria Pharmaceuticals Completes Enrollment in the Phase 2 IMPROVE-ISCHEMIA Clinical Trial of Ninerafaxstat in Patients with Stable Angina

Results from Two Phase 3 Studies Evaluating Mavacamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy Released

First International Guidelines on Heart Muscle Diseases Published

Healthcare is constantly evolving, finding new ways to innovate and advance digital tools and technology. With this comes the need for transformation to keep up with these advancements. DAIC spoke with Anne Snowdon, RN, PhD, FAAN, professor of strategy entrepreneurship, Odette Business School, University of Windsor, CEO of SCAN Health and Chief Scientific Research Officer, HIMSS Analytics, to find out more about the steps needed for this transformation and what we can expect to see in the future of healthcare.

Dr. Anne Snowdon is a Professor of Strategy and Entrepreneurship at the Odette School of Business, University of Windsor.  Currently, Dr. Snowdon is the Chief Scientific Research Officer for HIMSS, Vice Chair of the Board of the Directors for Alberta Innovates, and member of the Health Futures Council of Arizona State University (ASU).  She is an Adjunct Faculty at the Department of Computer Science at the University of Windsor, the School of Nursing at Dalhousie University and the Centre for Innovative Medical Technology (CIMT), at the University of Southern Denmark.  Dr. Snowdon is leading a national Community of Practice to advance supply chain resilience across Canada, she has published more than 150 research articles, papers and cases, has received over $24 million in research funding, holds patents and has commercialized a highly successful booster seat product for children traveling in vehicles and is a Fulbright Scholar. She holds a PhD in Nursing from the University of Michigan, an MSc from McGill University, and BScN from Western University.  

Find more HIMSS23 coverage here

VIDEO: Key Components to Creating and Implementing AI and Digital Transformation Solutions

VIDEO: The Benefits and Pitfalls of Artificial Intelligence in Healthcare

VIDEO: A Look at Cybersecurity and How Healthcare is at Risk

Related Digital Transformation Content:

Robocath Launches New Robotic Platform R-One+

VIDEO: Using Maturity Models to Measure Digital Health

VIDEO: Moving Digital Transformation Forward in Healthcare

VIDEO: Key Components to Creating and Implementing AI and Digital Transformation Solutions

VIDEO: The Benefits and Pitfalls of Artificial Intelligence in Healthcare

VIDEO: A Look at Cybersecurity and How Healthcare is at Risk

New ACC President Defines Priorities for Year Ahead

Health That Connects + Tech That Cares at HIMSS 2023

ACC22: Transforming Cardiovascular Care

With the help of artificial intelligence, cutting-edge technology is being developed that will help improve patient outcomes and build efficiencies in healthcare, which will help transform the future of healthcare delivery. DAIC sat down with Julius Bogdan, a leading expert in Digital transformation, Data and analytics, and Artificial intelligence and machine learning, to find out more about the inroads AI is making.

Julius is Vice President and General Manager, Digital Health Advisory Team for the Healthcare Information and Management Systems Society (HIMSS). In that role, he leads sales, business development, product management, product marketing and advisory services teams across the continent on digital health transformation. He is responsible for the growth of the HIMSS Analytics portfolio adoption, channel strategy, and cultivating relationships across the provider, payer and public sector health landscape. He also serves on the advisory council of various start-ups and early stage firms in finance and healthcare on technology trends, architecture and market analysis.

Find more HIMSS23 content here

VIDEO: A Look at Cybersecurity and How Healthcare is at Risk

VIDEO: Key Components to Creating and Implementing AI and Digital Transformation Solutions

Related Digital Transformation Content:

Robocath Launches New Robotic Platform R-One+

VIDEO: Using Maturity Models to Measure Digital Health

VIDEO: Moving Digital Transformation Forward in Healthcare

VIDEO: Key Components to Creating and Implementing AI and Digital Transformation Solutions

VIDEO: The Benefits and Pitfalls of Artificial Intelligence in Healthcare

VIDEO: A Look at Cybersecurity and How Healthcare is at Risk

New ACC President Defines Priorities for Year Ahead

Health That Connects + Tech That Cares at HIMSS 2023

ACC22: Transforming Cardiovascular Care

Managing Acute Coronary Syndromes in Women: Why and When is a Unique Approach Required features an in-depth interview with Malissa J. Wood, MD, FACC. Wood is the co-director of the Corrigan Women’s Heart Health Program at Massachusetts General Hospital Heart Center, and associate professor at Harvard Medical School. Here, she offers detailed guidance to cardiologists for improving the diagnosing and treatment of heart disease in women. Wood serves as the American College of Cardiology, ACC Chair, Board of Governors, and Secretary, Board of Trustees (2022-2023). This video interview is part of DAIC's One on One ... feature series that profiles a leader in cardiology to share insight, updates and initiatives on a range of hot topics impacting the cardiology community. The series also includes a feature profile and podcast.

Related content:

VIDEO: Precision Cardiovascular Medicine: The Next Frontier in Patient Care and Innovation

VIDEO: Unique Features of Coronary Artery Disease in Women

Treatment for Heart Attacks Improving but Gaps in Access Persist, New Study Shows

Closing the Gap in Healthcare by Addressing Gender Bias 

Diagnostic Differences in Women’s Heart Health  

VIDEO: Differences in Cardiac Complications and Presentation Between Men and Women — Interview with Cindy Grines, M.D.  

DAIC's Women's Cardiovascular Health Channel  

VIDEO: How to Build a Successful Women’s Heart Center — Interview with Malissa Wood, M.D.  

VIDEO: Creating a Cardio-Obstetrics Team — Doreen DeFaria Yeh, M.D. 

Related Content on New Technology and Ideas to Address Health Disparities: 

VIDEO: New Ideas in Addressing Cardiovascular Disease Disparities — Clyde Yancy, M.D 

VIDEO: How Smartphones May Revolutionize Healthcare in the Developing World —Interview with Jacques Kpodonu, M.D. 

VIDEO: Reducing Hypertension Among African-Americans — Interview with Kim Allan Williams, Sr., M.D. 

At TCT 2022, Jane Leopold, MD, a cardiologist at Brigham and Women’s Hospital; Director, Women's Interventional Cardiology Health Initiative; and Associate Professor, Harvard Medical School, moderated a late-breaker session on Clinical Science in Structural Heart Disease. Here, she highlights the key results of the clinical trials for DAIC/dicardiology.com.

Related TCT 2022 Coverage:

VIDEO: Precision Cardiovascular Medicine: The Next Frontier in Patient Care and Innovation

VIDEO: 3-Year Follow-up of the SYMPLICITY HTN-3 Trial

VIDEO: Unique Features of Coronary Artery Disease in Women

Cardiovascular Research Foundation’s (CRF) TCT 2022 in Review

Photo Gallery Highlighting TCT 2022

Cardiovascular Research Foundation’s (CRF) TCT 2022 in Review

TCT 2022 Honors Recipient of Thomas J. Linnemeier Young Investigator Award

TCT 2022 Announces Winner of Shark Tank Innovation Award

Educational Leaders Join Forces on Educational Opportunities

Top TCT 2022 Award Recipients announced by Cardiovascular Research Foundation (CRF)

At TCT 2022, Deepak Bhatt, MD, MPh, Executive Director of Interventional Cardiovascular Programs, Brigham and Women's Hospital, presented a late-breaker session on Long-Term Outcomes Following Catheter-Based Renal Denervation in Patients With Uncontrolled Hypertensions: 3-Year Follow-up of the SYMPLICITY HTN-3 Trial. He spoke with DAIC editors about the outcomes.

Related TCT 2022 Coverage:

VIDEO: Unique Features of Coronary Artery Disease in Women

Cardiovascular Research Foundation’s (CRF) TCT 2022 in Review

Photo Gallery Highlighting TCT 2022

Cardiovascular Research Foundation’s (CRF) TCT 2022 in Review

TCT 2022 Honors Recipient of Thomas J. Linnemeier Young Investigator Award

TCT 2022 Announces Winner of Shark Tank Innovation Award

Educational Leaders Join Forces on Educational Opportunities

Top TCT 2022 Award Recipients announced by Cardiovascular Research Foundation (CRF)

Enhanced features on the Philips EPIQ CVx ultrasound system provide a next level photorealistic 3D rendering, making it easy for users to interpret what they are seeing. The TrueVue feature enhances the sense of depth and space, producing images that appear natural and realistic to the human eye.  

Watch the video to check out how TrueVue can help improve views of LAA and MV morphology. 

The X5-1c transducer from Philips provides enhanced clinical information in transthoracic imaging over a standard phased array transducer. When combined with nSIGHT Plus image formation on the EPIQ CVx cardiology ultrasound system, the X5-1c transducer enables image quality rarely seen from a transthoracic transducer. 

Watch the video to learn about the benefits which may include decreased exam time due to faster access to echo windows, increased confidence in quantification results and more. 

Interview with Campbell Rogers, M.D., chief medical officer of HeartFlow which has developed a CT image-based fractional flow reserve (FFR-CT) algorithm. The technology was recently included as a recommendation for front line chest pain evaluations in the 2021 ACC/AHA chest pain evaluation guidelines.

The new guidelines gave high levels of evidence for the use of computed tomography and FFR-CT cardiac imaging as front line imaging modalities for chest pain evaluation.

Related Chest Pain Imaging Content:

First International Chest Pain Diagnosis Guidelines Released

VIDEO: Why the ASNC Did Not Endorse the 2021 Chest Pain Guidelines — Interview with ASNC President Dennis Calnon, M.D.

American Society of Nuclear Cardiology (ASNC) President Dennis Calnon, M.D., MASNC, FASE, FSCCT, director of cardiac imaging for McConnell Heart Hospital at Riverside Methodist Hospital, and director of nuclear imaging for Ohio Health Heart and Vascular Physicians in Columbus, explains why the society did not endorse the first-ever U.S. or international guideline for the evaluation and diagnosis of patients with acute or stable chest pain.

Nuclear myocardial perfusion imaging (MPI) has been a gold-standard for evaluation of coronary disease in patients for years, and it is included in the new guidelines. However, computed tomography angiography (CTA) has seen immense growth over the past decade and gained a prominent position in the guidelines as a front line imaging modality. This is due to nearly all hospital emergency rooms now having access to CT systems capable of performing immediate cardiac exams. CT has been seen mainly as an anatomical imaging test, but it also can be used for myocardial perfusion imaging using iodine contrast. While CT has had limits with its ability to image through heavily calcified vessels or stents, that is changing with new CT technologies now coming into service.

One new CT technology that is prominently included I the new chest pain guidelines is CT fractional flow reserve (FFR-CT) imaging.  This uses a computational fluid dynamics algorithm to analyze a patient's CTA. It sends back a report and an interactive 3D reconstruction of all the coronary vessels that shows a color coded drop in FFR ratios, which is a measure of blood flow. Past a certain threshold, the reduced flow needs to be treated with revascularization. Lower level blockages can be treated with drug therapies. FFR-CT is widely expected in the coming years to become a gate keeper for invasive diagnostic angiograms. The hope is it will eliminate the need for the majority of cath lab angiogram exams and only send patients to the lab that need a stent or angioplasty. 

However, the ASNC had major issues with FFR-CT being included in the chest pain guidelines. Its board members argued there is need for more evidence and there should have been more information contraindications for its use, which was included on other imaging modalities in the guidelines. They also argued access to the technology has been very limited. Calnon explains more detail in the video on why this was a sticking point and caused the ASNC to not endorse the guidelines.

Read more in the article — First International Chest Pain Diagnosis Guidelines Released

Siddharth Singh, M.D., director of the COVID-19 heart program, staff cardiologist and echocardiographer, Cedars-Sinai Hospital, explains what has been learned in the first year of the hospital's long-COVID clinic. Cedar-Sinai was one of the first hospitals in the U.S. to create a cardiac long-COVID clinic. As of January 2022, the clinic has been more than 120 long-COVID patients with cardiac specific complains. 

"Depending on what study you read, a percentage of patients with acute COVID infection will go on to develop long-lasting sequelae, but typically the percentage falls over time," explained Siddharth Singh, M.D., director of the COVID heart program, staff cardiologist and echocardiographer, Cedars-Sinai Hospital.

He said studies show between 10-25 percent of COVID patients will experience at least one disabling long-COVID symptom six months after their acute infection.

Cedars-Sinai long-COVID has seen over 500 patients since late 2020. Of these, 120 were referred for cardiac evaluations. The most common presentations in those patients include:
   • Shortness of breath
   • Exertional intolerance
   • Chest pain
   • Heart palpitations  
   • Sensations of light-headedness and dizziness
   • Insomnia
   • Brain fog 
   • Constipation
   • Diarrhea
   • Numbness or tingling in the extremities
   • Longer lasting issues with smell and taste

Singh also said many patients experience anxiety and depression due to the continued symptoms, and are concerned the issues they have from COVID may be permanent. Both Baggish and Trivax also reported seeing these issues in many of their patients.

In a smaller subset of patients these clinics have found lingering pericarditis or myocarditis. Most of these patients reported developing chest pain within two week or so after their acute infection. Singh said abnormalities can be imaged using echo and MRI.

"They do typically have abnormalities on imaging. But reassuringly, of all the patients who came to our clinic with these issues, we did not see any decline in left ventricular ejection fraction or systolic function," Singh stressed.

Patients with lingering pericarditis or myocarditis issues are treated with anti-inflammatories. Singh reinforced that the number of patients treated for this have been very low.

Singh said the arrhythmias he has seen include atrial fibrillation (AF) and supraventricular tachycardia. He noted ventricular tachycardia is very rare in these patients. In discussions with his electrophysiology (EP) colleagues, Singh believes the issues with post-COVID arrhythmias often comes down to the substrate of the patient's heart. He said the more cardiovascular disease, cardiomyopathy, scarring, or previous AF a patient has, the more predisposed they are to developing an arrhythmia after a COVID infection. 

Watch more of the interview with Singh in the VIDEO: Examination of Cardiac COVID Long-Haulers
 

Related Long-COVID Content:

What We Know About Cardiac Long-COVID Two Years Into the Pandemic 

VIDEO: Long-term Cardiac Impacts of COVID-19 Two Years Into The Pandemic — Interview with Aaron Baggish, M.D.

VIDEO: Long-COVID Presentations in Cardiology at Beaumont Hospital — Interview with Justin Trivax, M.D.

VIDEO: Examination of Cardiac COVID Long-Haulers — Interview with Siddharth Singh, M.D.

Find more COVID news and video

Justin Trivax, M.D., an interventional cardiologist who works with long-COVID patients at Beaumont Hospital, explains some of the common symptoms and their prevalence in the Beaumont long-COVID clinic. 

COVID long hauler syndrome is no longer seen as a big mystery because large numbers of these patients have been seen and treated. The bottom line is that while long-hauler symptoms are an issue for patients, they do not appear to be life-threatening and the big fear of large numbers of new heart failure patients post infection has not materialized.

"Interestingly, the patients do get better. It is a slow process, but by the one-year point we do see improvement in patients with this prolonged syndrome," reassured Trivax.

Many of the patients Trivax has seen only had a mild case of COVID, but presenting months later with cardiac issues. Trivax said these patients often test troponin positive. The question as to what is causing this often results in a cardiac MRI.

"There are also patients who had very mild symptoms [during their COVID infection] and those patients don't have a major event, however, they may have those prolonged symptoms," Trivax said. "We see this in the MRI studies that have been performed. But, what these abnormal cardiac MRIs really mean, we don't quite know. We don't have any long-term data for these COVID patients."

Read more of his observations in the article What We Know About Cardiac Long-COVID Two Years Into the Pandemic

Related Long-COVID Content:

What We Know About Cardiac Long-COVID Two Years Into the Pandemic 

VIDEO: Cardiac Presentations in COVID Long-haulers at Cedars-Sinai Hospital — Interview with Siddharth Singh, M.D.

VIDEO: Long-term Cardiac Impacts of COVID-19 Two Years Into The Pandemic — Interview with Aaron Baggish, M.D.

VIDEO: Long-COVID Presentations in Cardiology at Beaumont Hospital — Interview with Justin Trivax, M.D.

VIDEO: Examination of Cardiac COVID Long-Haulers — Interview with Siddharth Singh, M.D.

Find more COVID news and video

Orlando Simonetti, Ph.D., professor, cardiovascular medicine, worked with Siemens to help develop a new, lower-field magnetic resonance imaging (MRI) system, the Magnetom Free.Max. It can scan patients that previously may have been contraindicated because of implantable medical devices. The first system installed in the U.S. is at The Ohio State University Wexner Medical Center. It has a much lower magnetic field and a larger patient opening, removing barriers to MRI imaging for many patients.

Simonetti and his colleagues developed new techniques to boost the signal-to-noise ratio in MRI machines, which allowed the creation of a machine with a lower magnetic field strength that still enables high quality images.

The system gained FDA clearance in July 2021 and was featured by Siemens at the Radiological Society of North America (RSNA) 2021 meeting.

The interview and footage was provided by The Ohio University State University Wexner Medical Center.

Read more in the article New FDA-approved MRI Expands Access to Life-saving Imaging.

Jean Jeudy, M.D., professor of radiology and vice chair of informatics at the University of Maryland School of Medicine, presented a late-breaking study at the 2021 Radiological Society of North America (RSNA) meeting on COVID-19 linked myocarditis in college athletes. 

A small but significant percentage of college athletes with COVID-19 develop myocarditis, a potentially dangerous inflammation of the heart muscle, that can only be seen on cardiac MRI, according to the study Jeudy presented. Myocarditis, which typically occurs as a result of a bacterial or viral infection, can affect the heart’s rhythm and ability to pump and often leaves behind lasting damage in the form of scarring to the heart muscle. It has been linked to as many as 20% of sudden deaths in young athletes. The COVID-19 pandemic raised concerns over an increased incidence of the condition in student-athletes.

For the new study, clinicians at schools in the highly competitive Big Ten athletic conference collaborated to collect data on the frequency of myocarditis in student-athletes recovering from COVID-19 infection. Conference officials had required all athletes who had COVID-19 to get a series of cardiac tests before returning to play, providing a unique opportunity for researchers to collect data on the athletes’ cardiac status.

Jeudy serves as the cardiac MRI core leader for the Big Ten Cardiac Registry. This registry oversaw the collection of all the data from the individual schools of the Big Ten conference. He reviewed the results of 1,597 cardiac MRI exams collected at the 13 participating schools. 

Thirty-seven of the athletes, or 2.3%, were diagnosed with COVID-19 myocarditis, a percentage on par with the incidence of myocarditis in the general population. However, an alarmingly high proportion of the myocarditis cases were found in athletes with no clinical symptoms. Twenty of the patients with COVID-19 myocarditis (54%) had neither cardiac symptoms nor cardiac testing abnormalities. Only cardiac MRI identified the problem.

Read more details in the article COVID-19 Linked to Heart Inflammation in College Athletes.

Related COVID-19 Imaging and Myocarditis Content:

Overview of Myocarditis Cases Caused by the COVID-19 Vaccine

COVID-19 Linked to Heart Inflammation in College Athletes — RSNA 2021 late-breaker

VIDEO: Cardiac MRI Assessment of Non-ischemic Myocardial Inflammation Caused by COVID-19 Vaccinations — Interview with Kate Hanneman, M.D.

Cardiac MRI of Myocarditis After COVID-19 Vaccination in Adolescents

Large International Study Reveals Spectrum of COVID-19 Brain Complications - RSNA 2021 late-breaker

COVID-19 During Pregnancy Doesn’t Harm Baby’s Brain

VIDEO: Large Radiology Study Reveals Spectrum of COVID-19 Brain Complications — Interview with Scott Faro, M.D.

FDA Adds Myocarditis Warning to COVID mRNA Vaccine Clinician Fact Sheets

Small Number of Patients Have Myocarditis-like Illness After COVID-19 Vaccination

Kate Hanneman, M.D., MPH FRCPC, director of cardiac imaging research JDMI, and the medical imaging site director at Toronto General Hospital, Women’s College Hospital, was an author on a recent overview of cardiac MRI assessments of non-ischemic myocardial inflammation caused by the COVID-19 vaccine. She presented this study and other related data at the 2021 Radiological Society of North America (RSNA) meeting. 

The rare side effect from the COVID vaccine is seen mainly in young men between ages 12-29. It appears to resolve on its own after a couple days, but longer term monitoring is needed to show if there is any lasting cardiac damage. A small number of single cases with follow up MRI imaging so far have not shown long term damage. 

Hanneman noted the incidence of vaccine-related myocarditis is very rare and people have a much high probability of getting much more serious COVID-viral myocarditis is they are not vaccinated. She said so the risk-vs-benefit analysis currently shows it is better to get vaccinated to prevent or lessen the effects of COVID. 

Related COVID-19 Imaging Content:

Overview of Myocarditis Cases Caused by the COVID-19 Vaccine

COVID-19 Linked to Heart Inflammation in College Athletes — RSNA 2021 late-breaker

Cardiac MRI of Myocarditis After COVID-19 Vaccination in Adolescents

Large International Study Reveals Spectrum of COVID-19 Brain Complications - RSNA 2021 late-breaker

COVID-19 During Pregnancy Doesn’t Harm Baby’s Brain

VIDEO: Large Radiology Study Reveals Spectrum of COVID-19 Brain Complications — Interview with Scott Faro, M.D.

FDA Adds Myocarditis Warning to COVID mRNA Vaccine Clinician Fact Sheets

Small Number of Patients Have Myocarditis-like Illness After COVID-19 Vaccination

Christine Albert, M.D., MPH, professor, chair of the Department of Cardiology and the Lee and Harold Kapelovitz Distinguished Chair in Cardiology, and former president of the Heart Rhythm Society (HRS). She spoke at the American Heart Association (AHA) 2021 meeting on innovations in electrophysiology (EP) technologies. 

Advances she discusses include:
   • Leadless pacing and CRT systems  
   • Wearable patch heart monitors and that are largely replacing traditional Holter monitors.
   • Pulsed field ablation (also called electroporation) that may improve cardiac ablations and prevent damage to underlying tissues.
   • Cryo-ablation balloons.
   • Improved EP mapping technologies.
   • and left atrial appendage (LAA) occluders.

Find more EP lab technology news

Find More AHA 2021 Late-breaking News

Susan Cheng, M.D., MPH, director of the Institute for Research on Healthy Aging in the Department of Cardiology at Cedars-Sinai and the Erika J. Glazer Chair in Women's Cardiovascular Health and Population Science, led a discussion at the American Heart Association (AHA) 2021 meeting on novel therapeutics for the lipid lowering treatments. 

She discusses bempedoic acid, inclisiran to reduce LDL-C, icosapent ethyl and the use of genetic testing to further reduce high low-density lipoprotein (LDL) in patients were statin therapy is not enough.

Cheng discusses more in the VIDEO: Use of Genetic Testing to Tailor Lipid Lowering Therapies.

Find more AHA 2021 late-breaking studies and video

Srihari Naidu, M.D., FACC, FAHA, FSCAI, is the director of both the cardiac cath labs and Hypertrophic Cardiomyopathy National Center of Excellence at Westchester Medical Center in New York, and chair of Society for Cardiovascular Angiography and Interventions (SCAI) SHOCK committee. He presented a new cardiogenic shock classification system at the 2021 Transcatheter Cardiovascular Therapeutics (TCT) meeting.

Related Cardiogenic Shock Content:

VIDEO: Final Results of the National Cardiogenic Shock Initiative Show 71 Percent Survival — Interview with William O’Neill, M.D.

New Approaches to Reduce Cardiogenic Shock Mortality

VIDEO: Tufts Uses a Hemodynamic Support Algorithm to Determine What Devices to Use

VIDEO: Hemodynamic Support Protocols at Henry Ford Hospital

National Cardiogenic Shock Initiative Protocol Shows 71 Percent Survival 

VIDEO: New Research in Cardiogenic Shock at Tufts Medical Center

VIDEO: The Importance of Ventricular Unloading in AMI and Cardiogenic Shock — Interview with Nevin Kapur, M.D.

VIDEO: How to Reduce Cardiogenic Shock Mortality by 50 Percent — Interview with Babar Basir, D.O.

SCAI Releases New Consensus Document on Classification Stages of Cardiogenic Shock

10 Reasons Why it is Time to Learn More About Cardiogenic Shock — by Emmanouil S. Brilakis, M.D.

Find links to all the TCT 2021 late-breakers

Find more TCT news